HRP20150513T1 - Novi polimorf - Google Patents
Novi polimorf Download PDFInfo
- Publication number
- HRP20150513T1 HRP20150513T1 HRP20150513TT HRP20150513T HRP20150513T1 HR P20150513 T1 HRP20150513 T1 HR P20150513T1 HR P20150513T T HRP20150513T T HR P20150513TT HR P20150513 T HRP20150513 T HR P20150513T HR P20150513 T1 HRP20150513 T1 HR P20150513T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid form
- form according
- nocturia
- vasopressin
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
| EP11714079.8A EP2552910B1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150513T1 true HRP20150513T1 (hr) | 2015-06-05 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150513TT HRP20150513T1 (hr) | 2010-04-01 | 2011-03-31 | Novi polimorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (enExample) |
| EP (1) | EP2552910B1 (enExample) |
| JP (1) | JP5802737B2 (enExample) |
| KR (1) | KR101792621B1 (enExample) |
| CN (1) | CN102918038B (enExample) |
| CA (1) | CA2795109C (enExample) |
| DK (1) | DK2552910T3 (enExample) |
| ES (1) | ES2538085T3 (enExample) |
| GB (1) | GB201005623D0 (enExample) |
| HR (1) | HRP20150513T1 (enExample) |
| HU (1) | HUE026442T2 (enExample) |
| ME (1) | ME02102B (enExample) |
| MX (1) | MX2012011382A (enExample) |
| PL (1) | PL2552910T3 (enExample) |
| PT (1) | PT2552910E (enExample) |
| RS (1) | RS53956B1 (enExample) |
| RU (1) | RU2559633C2 (enExample) |
| SI (1) | SI2552910T1 (enExample) |
| SM (1) | SMT201500107B (enExample) |
| WO (1) | WO2011121308A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| EP4616852A3 (en) | 2015-07-22 | 2025-10-22 | Anavex Life Sciences Corp. | Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| ES2229523T3 (es) | 1997-07-30 | 2005-04-16 | Wyeth | Agonistas triciclicos de la vasopresina. |
| IL133788A0 (en) | 1997-07-30 | 2001-04-30 | American Home Prod | Tricyclic vasopressin agonists |
| WO2000046227A1 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
| PT1149096E (pt) | 1999-02-04 | 2003-03-31 | Wyeth Corp | N-oxidos de piridina triciclicos agonistas de vasopressina |
| WO2000046228A2 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| CN1339035A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂 |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 RS RS20150258A patent/RS53956B1/sr unknown
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko not_active Expired - Fee Related
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en not_active Ceased
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 HR HRP20150513TT patent/HRP20150513T1/hr unknown
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101792621B1 (ko) | 2017-11-02 |
| HUE026442T2 (en) | 2016-06-28 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| KR20130023218A (ko) | 2013-03-07 |
| CA2795109A1 (en) | 2011-10-06 |
| GB201005623D0 (en) | 2010-05-19 |
| JP2013523706A (ja) | 2013-06-17 |
| DK2552910T3 (en) | 2015-04-07 |
| ME02102B (me) | 2015-10-20 |
| CN102918038A (zh) | 2013-02-06 |
| PL2552910T3 (pl) | 2015-07-31 |
| CA2795109C (en) | 2018-04-17 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| MX2012011382A (es) | 2013-01-29 |
| US20140296213A1 (en) | 2014-10-02 |
| EP2552910A1 (en) | 2013-02-06 |
| EP2552910B1 (en) | 2015-03-11 |
| RS53956B1 (sr) | 2015-08-31 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
| ES2538085T3 (es) | 2015-06-17 |
| CN102918038B (zh) | 2015-09-09 |
| PT2552910E (pt) | 2015-05-13 |
| JP5802737B2 (ja) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02102B (me) | Novi polimorf | |
| ES2659758T3 (es) | Antagonistas de receptores de 5-HT3 | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| EP4574210A3 (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| EP2528618A4 (en) | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS | |
| JP2014162794A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| NZ603043A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| MX2012012571A (es) | Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas. | |
| CL2009001125A1 (es) | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. | |
| JP2012036197A5 (enExample) | ||
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| ME02805B (me) | Inhibitori cdc7 | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| JP2013522326A5 (enExample) | ||
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| JP2014530818A5 (enExample) | ||
| PH12016502034B1 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| MX356105B (es) | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. | |
| GEAP201914563A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PH12013502691A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| EA201101207A1 (ru) | Применение антагонистов рецептора nk |